Clinical Trial Detail

NCT ID NCT03417544
Title Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Nancy Lin, MD
Indications

Her2-receptor positive breast cancer

Therapies

Atezolizumab + Pertuzumab + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST